Loading...
•
Jun 30, 2020
Glaukos Q2 2020 Earnings Report
Glaukos's net sales decreased due to COVID-19 disruptions, while employees remained dedicated to strategic objectives.
Key Takeaways
Glaukos Corporation reported a decrease in net sales for Q2 2020, primarily due to disruptions associated with COVID-19. The company is encouraged by the initial return of elective procedures and remains focused on advancing its mission.
Q2 2020 net sales were $31.6 million, compared to $58.6 million in Q2 2019.
Glaucoma Q2 2020 net sales were $24.9 million, compared to $58.6 million in Q2 2019.
Corneal Health Q2 2020 net sales were $6.6 million.
Gross margin for the second quarter of 2020 was approximately 31%, compared to approximately 87% in the same period in 2019.
Glaukos
Glaukos
Glaukos Revenue by Segment
Revenue by Segment
Glaucoma Revenue
CapyFin.com Forward Guidance
Glaukos has withdrawn its previously announced annual guidance for 2020 due to the rapidly evolving environment and continued uncertainties from the impact of COVID-19.